Get the Stockscreener App
1.515
12.22%
0.165
Vivani Medical Inc stock is traded at $1.515, with a volume of 1.40M.
It is up +12.22% in the last 24 hours and up +31.74% over the past month.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.
See More
Previous Close:
$1.35
Open:
$1.36
24h Volume:
1.40M
Relative Volume:
3.29
Market Cap:
$130.37M
Revenue:
-
Net Income/Loss:
$-27.09M
P/E Ratio:
-3.7537
EPS:
-0.4036
Net Cash Flow:
$-26.52M
1W Performance:
+23.17%
1M Performance:
+31.74%
6M Performance:
+15.65%
1Y Performance:
+19.29%
1-Day Range:
$1.33
$1.58
1-Week Range:
$1.23
$1.58
52-Week Range:
$0.9228
$1.92
Vivani Medical Inc Stock (VANI) Company Profile
Name
Vivani Medical Inc
Sector
Industry
Phone
415-506-8462
Address
1350 S. LOOP ROAD, ALAMEDA
Compare VANI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VANI
Vivani Medical Inc
|
1.5118 | 116.42M | 0 | -27.09M | -26.52M | -0.4036 |
VRTX
Vertex Pharmaceuticals Inc
|
508.88 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.60 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.29 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.79 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
188.12 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivani Medical Inc Stock (VANI) Latest News
symbol__ Stock Quote Price and Forecast - CNN
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - riauone.com
Vivani Flat on Hookup with Novo - Baystreet.ca
Sector Update: Healthcare - Moomoo
Vivani Medical Partners with Novo Nordisk to Evaluate Ultra Long-Acting Semaglutide Implant for Weight Management - Minichart
Vivani in pact with Novo to study Wegovy implant (NVO:NYSE) - Seeking Alpha
Novo Nordisk to evaluate Vivani Medical's semaglutide implant - marketscreener.com
Vivani Advances GLP-1 Implant Program With Novo Nordisk - TipRanks
Vivani Medical Says Novo Nordisk to Evaluate Semaglutide Implant for Weight Management - marketscreener.com
Vivani Medical to Merge Cortigent Into ClearOne; Receives 12.5M Shares, Deal Needs $10–15M Financing - TradingView
Novo Nordisk will evaluate Vivani’s semaglutide implant for weight loss - Stock Titan
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management | 主頁新聞 - etnet 經濟通
ClearOne to Acquire Cortigent, Inc. in Major Merger with Vivani Medical Subsidiary, Paving Way for Precision Neurostimulation Advances 1 – Minichart - Minichart
ClearOne to Merge with Cortigent, Pivoting to Neurotech - TipRanks
ClearOne (Nasdaq: CLRO) sets Cortigent merger, Vivani majority stake and $10–15M raise - Stock Titan
Vivani strikes reverse-merger agreement with ClearOne for BCI business - Yahoo Finance
We're Keeping An Eye On Vivani Medical's (NASDAQ:VANI) Cash Burn Rate - Sahm
ClearOne (CLRO) to Acquire Vivani Medical's Cortigent in Strategic Merger - GuruFocus
Why Did CLRO Stock Surge More Than 170% Today? - TradingView
ClearOne agrees merger to acquire Cortigent - grafa.com
Vivani to sell neurotech subsidiary Cortigent to ClearOne - MassDevice
ClearOne enters into merger agreement with Cortigent - TipRanks
ClearOne to acquire Cortigent in reverse merger transaction By Investing.com - Investing.com South Africa
ClearOne to acquire Cortigent in reverse merger transaction - Investing.com UK
Lake Street Maintains Vivani Medical(VANI.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Vivani to merge Cortigent unit with ClearOne in $10-15M deal - Investing.com South Africa
Clearone Announces Entry Into Merger Agreement With Cortigent, Inc., A Wholly-Owned Subsidiary Of Vivani Medical - TradingView
Vivani Announces Entry into Merger Agreement Between Wholly - GlobeNewswire
Price to earnings forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Vivani Medical Advances SLIM-1 Trial for Obesity Treatment - TipRanks
Form 4 Vivani Medical Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to EBIT forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Enterprise value to EBIT forward of Vivani Medical Inc. – DUS:U5P - TradingView
Vivani Medical Inc. Actuals & Estimates (NASDAQ:VANI) - TradingView
Price to book forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Price to book forward of Vivani Medical Inc. – DUS:U5P - TradingView
Vivani Medical appoints August Moretti to board of directors By Investing.com - Investing.com Australia
Vivani’s Board Overhaul Signals High-Stakes Push into GLP-1 Market - BriefGlance
Vivani Medical appoints August Moretti to board of directors - Investing.com
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - GlobeNewswire
Price to sales forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingView
Form 4 Vivani Medical Inc For: 25 June By Investing.com - Investing.com Australia
Price to sales forward of Vivani Medical Inc. – DUS:U5P - TradingView
Enterprise value to EBITDA forward of Vivani Medical Inc. – DUS:U5P - TradingView
Price to earnings forward of Vivani Medical Inc. – DUS:U5P - TradingView
Enterprise value to revenue forward of Vivani Medical Inc. – DUS:U5P - TradingView
Vivani Medical receives approval to start semaglutide implant trial - Investing.com
Vivani Medical (VANI) Secures Approval for Phase 1 Clinical Tria - GuruFocus
Vivani Medical receives approval to start semaglutide implant trial By Investing.com - Investing.com Australia
Vivani Medical Receives Regulatory Approval to Test Potential Weight Loss Drug Implant - marketscreener.com
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management - GlobeNewswire
Vivani Medical Inc Stock (VANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.39%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):